title: Effect of prophylactic treatment with intravesical epirubicin on recurrence of superficial bladder cancer--The 6th Trial of the Japanese Urological Cancer Research Group (JUCRG): a randomized trial of intravesical epirubicin at dose of 20mg/40ml, 30mg/40ml, 40mg/40ml.
abstract: OBJECTIVE
  We compared the prophylactic efficacy and safety of epirubicin (EPI) in primary superficial bladder cancer.
  
  
  METHODS
  The major inclusion criteria were primary superficial bladder tumour (Ta, T1, G1, G2) and new cases of primary multiple tumours, or recurrent cases. The major exclusion criteria were Tis or G3 tumours. Group A received 17 doses of EPI 20mg/40ml over a period of 12 months for a total dose of 340mg. In contrast, Group B received 12 doses of EPI 30mg/40ml over a period of 7 months, while Group C received 9 doses of EPI 40mg/40ml over a period of 4 months, both for a total dose of 360mg. This study enrolled a total of 622 patients diagnosed as having primary superficial bladder cancer during the period from June 1994 through November 1996 at the 118 institutions. Follow-up of the patients was conducted through October 1999.
  
  
  RESULTS
  The relationship between the EPI concentration and the recurrence-free rate was evaluated by Tarone's test, and it was found that the recurrence-free rate became significantly higher as the drug concentration increased (p=0.0375). In the safety evaluation, with regard to adverse drug reactions, pollakiuria and pain on urination occurred at significantly higher incidences as the concentration of the EPI solution increased.
  
  
  CONCLUSIONS
  The greatest effect of intravesical instillation of EPI after TUR-BT was shown by the regimen using the highest concentration of the drug solution which was administered during a short period of time.
authors.affiliation: Department of Urology, Nissay Hospital, 6-3-8 Tachiuribor, Nishi-ku, Osaka 550-0012, Japan. Takahiro.yamaguchi@japan.pfizer.com
authors.forename: Masao
authors.initials: M
authors.lastname: Kuroda
authors.forename: Tadao
authors.initials: T
authors.lastname: Niijima
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Kotake
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Akaza
authors.forename: Shiro
authors.initials: S
authors.lastname: Hinotsu
mesh_terms: D000283:Administration, Intravesical; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000517:prevention & control*; D015251:Epirubicin / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000517:prevention & control
chemical_list: D000903:Antibiotics, Antineoplastic; D015251:Epirubicin